Fig. 1
From: CCN3 is dynamically regulated by treatment and disease state in multiple sclerosis
Plasma CCN3 levels are altered by MS disease phase and treatment. Plasma CCN3 levels are compared in healthy controls and MS (a), controls and MS disease phase (b), RRMS treatment groups (c) and matched samples from RRMS patients during relapse or remittance (d). Detection of plasma-derived CCN3 by western blot (e). Abbreviations: HC, healthy control; MS, multiple sclerosis; RRMS, relapsing-remitting MS; Prog MS, progressive MS; TN, treatment-naïve; Nat, natalizumab treatment; IFN, interferon-β treatment; Ctl, h295-R-conditioned medium as positive control